Explore 3 Stock Ideas & Industry Insights Download Free Report

AngioDynamics Inc

Healthcare US ANGO

12.37USD
-0.02(0.16%)

Last update at 2026-06-23T20:00:00Z

Day Range

12.3512.66
LowHigh

52 Week Range

8.3613.99
LowHigh

Fundamentals

  • Previous Close 12.39
  • Market Cap442.94M
  • Volume263238
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.65900M
  • Revenue TTM313.72M
  • Revenue Per Share TTM7.59
  • Gross Profit TTM 170.34M
  • Diluted EPS TTM-0.76

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Income before tax -34.03200M -191.63800M -54.43700M -29.94900M -36.05200M
Minority interest - - - - -
Net income -33.99300M -184.34900M -52.44200M -26.54700M -31.54800M
Selling general administrative 42.09M 41.16M 40.00M 38.45M 35.92M
Selling and marketing expenses 103.14M 102.82M 104.25M 95.30M 81.31M
Gross profit 157.71M 154.70M 174.25M 165.73M 156.79M
Reconciled depreciation 25.80M 27.71M 30.87M 29.35M 25.92M
Ebit -24.06200M -33.84400M -19.23300M -19.00700M -14.87000M
Ebitda 1.74M -6.13200M 11.64M 10.34M 11.05M
Depreciation and amortization 25.80M 27.71M 30.87M 29.35M 25.92M
Non operating income net other - - -0.55400M -0.79000M 0.09M
Operating income -39.95400M -192.43500M -19.23300M -19.00700M -14.87000M
Other operating expenses 332.45M 496.35M 357.43M 334.44M 305.97M
Interest expense - 1.61M 2.70M 0.69M 0.86M
Tax provision -0.03900M -7.28900M -1.99500M -3.40200M -4.50400M
Interest income - - - - -
Net interest income 0.98M 1.61M -2.70200M -0.68800M -0.86100M
Extraordinary items - - - - -
Non recurring - - 32.50M 10.25M 20.32M
Other items - - - - -
Income tax expense -0.03900M -7.28900M -1.99500M -3.40200M -4.50400M
Total revenue 292.50M 303.91M 338.75M 316.22M 291.01M
Total operating expenses 197.66M 347.13M 192.93M 183.95M 171.75M
Cost of revenue 134.79M 149.22M 164.51M 150.49M 134.22M
Total other income expense net 5.92M 0.80M -35.20400M -10.94200M -21.18200M
Discontinued operations - - - - -
Net income from continuing ops -33.99300M -184.34900M -52.44200M -26.54700M -31.54800M
Net income applicable to common shares - - -52.44200M -26.54700M -31.54800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Total assets 280.14M 317.67M 532.64M 552.75M 561.44M
Intangible assets 69.12M 77.38M 111.14M 152.38M 168.98M
Earning assets - - - - -
Other current assets 7.29M 12.97M 4.62M 2.20M 1.76M
Total liab 97.17M 112.08M 154.34M 128.26M 121.98M
Total stockholder equity 182.97M 205.59M 378.30M 424.49M 439.46M
Deferred long term liab - - 12.81M 16.04M 19.95M
Other current liab 42.91M 50.91M 43.38M 21.46M 37.95M
Common stock 0.39M 0.39M 0.38M 0.38M 0.38M
Capital stock 0.39M 0.39M 0.38M 0.38M 0.38M
Retained earnings -429.19700M -395.20400M -210.85500M -158.41300M -131.86600M
Other liab - - 17.38M 24.20M 37.08M
Good will - 0.00000M 159.24M 201.06M 201.32M
Other assets - - 49.22M 10.96M 3.81M
Cash 55.89M 76.06M 44.62M 28.82M 48.16M
Cash and equivalents - - - - -
Total current liabilities 76.20M 91.16M 83.83M 74.32M 57.58M
Current deferred revenue - - -14.76100M 16.04M -
Net debt -55.89300M -71.32800M 5.20M 4.96M -28.16100M
Short term debt 1.84M 1.98M 14.76M 8.78M -
Short long term debt - 4.73M 14.76M 8.78M -
Short long term debt total 3.95M 5.91M 49.82M 33.78M 20.00M
Other stockholder equity 613.80M 604.77M 593.49M 581.16M 567.79M
Property plant equipment - - 44.38M 45.01M 37.07M
Total current assets 168.32M 193.25M 163.54M 143.34M 140.88M
Long term investments - - - - -
Net tangible assets - - 378.30M 71.05M 69.16M
Short term investments - - - - -
Net receivables 43.14M 43.61M 52.83M 52.30M 35.41M
Long term debt - - 49.82M 25.00M 20.00M
Inventory 62.01M 60.62M 55.33M 51.39M 48.61M
Accounts payable 33.29M 37.75M 40.45M 28.05M 19.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.02300M -4.36500M -4.72300M 1.36M 3.15M
Additional paid in capital - - - - -
Common stock total equity - - 0.38M 0.38M 0.38M
Preferred stock total equity - - - - -
Retained earnings total equity - - -210.85500M -158.41300M -131.86600M
Treasury stock - - -5.71400M -5.71400M -5.71400M
Accumulated amortization - - - - -
Non currrent assets other 10.40M 5.57M 54.33M -5.07400M 13.19M
Deferred long term asset charges - - - - -
Non current assets total 111.82M 124.42M 369.10M 409.41M 420.56M
Capital lease obligations - - - - -
Long term debt total - - 49.82M 25.00M 20.00M
Breakdown 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Type yearly yearly yearly yearly yearly
Date 2025-05-31 2024-05-31 2023-05-31 2022-05-31 2021-05-31
Investments -10.17800M 123.72M -9.74600M -11.41000M -8.52400M
Change to liabilities - - 2.14M 3.91M 4.88M
Total cashflows from investing activities -10.17800M - -9.74600M -19.30700M -13.71100M
Net borrowings 0.00000M - 24.25M 5.00M -20.00000M
Total cash from financing activities -0.25500M -64.24800M 25.42M 7.68M -16.98600M
Change to operating activities - - 0.33M -5.01200M -3.18100M
Net income -33.99300M -184.34900M -52.44200M -26.54700M -31.54800M
Change in cash -20.16300M 31.44M 15.79M -19.33600M -6.27400M
Begin period cash flow 76.06M 44.62M 28.82M 48.16M 54.44M
End period cash flow 55.89M 76.06M 44.62M 28.82M 48.16M
Total cash from operating activities -10.12800M -28.15800M 0.08M -7.19400M 24.09M
Issuance of capital stock - - - - -
Depreciation 25.80M 27.71M 30.87M 29.35M 25.92M
Other cashflows from investing activities -5.71400M - -5.93400M -15.01000M -8.52400M
Dividends paid - - - - -
Change to inventory -1.34700M -9.41000M -8.19800M -2.79600M 11.54M
Change to account receivables 0.02M 7.89M -1.29900M -17.15100M -4.16200M
Sale purchase of stock -1.67000M - - - -
Other cashflows from financing activities -4.74700M -15.00000M 0.42M 2.68M -13.71100M
Change to netincome - - 28.50M 11.05M 23.00M
Capital expenditures 4.46M 5.77M 4.35M 4.30M 13.71M
Change receivables - - -1.29900M -17.15100M -4.16200M
Cash flows other operating - - 0.51M -6.28100M -5.53000M
Exchange rate changes - - - - 0.33M
Cash and cash equivalents changes - - 15.75M -18.81800M -6.27400M
Change in working capital -14.11200M 14.42M -7.02600M -21.04700M 9.07M
Stock based compensation 9.77M 10.53M 11.16M 10.69M 8.62M
Other non cash items 3.39M 111.50M 19.82M 4.07M 16.83M
Free cash flow -14.59200M -33.92600M -4.27400M -11.49100M 10.38M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANGO
AngioDynamics Inc
-0.02 0.16% 12.37 - 96.15 1.41 2.56 1.29 147.24
ISRG
Intuitive Surgical Inc
0.23 0.06% 403.18 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme
- -% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
-0.49 0.51% 95.87 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
3.21 2.28% 143.92 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics Inc

14 Plaza Drive, Latham, NY, United States, 12110

Key Executives

Name Title Year Born
Mr. James C. Clemmer CEO, Pres & Director 1964
Mr. Stephen A. Trowbridge Exec. VP & CFO 1974
Mr. David D. Helsel Sr. VP of Global Operations and R&D 1964
Mr. Chad T. Campbell Sr. VP & GM of Vascular Access Global Bus. Unit 1971
Ms. Laura Piccinini Sr. VP & GM of International 1970
Mr. Richard C. Rosenzweig Sr. VP, Gen. Counsel & Company Sec. 1967
Mr. Benjamin H. Davis Sr. VP of Bus. Devel. 1964
Ms. Marna I. Bronfen-Moore Sr. VP of HR 1967
Mr. Warren G. Nighan Sr. VP of Quality & Regulatory Affairs 1969
Ms. Kim L. Seabury Sr. VP of Information Technology 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.